Management of Diabetic Patients with Statin Intolerance and Elevated ALT

Introduction to Ezetimibe Therapy

• The American College of Cardiology recommends ezetimibe as the preferred non-statin agent in diabetic patients requiring lipid-lowering therapy, due to its favorable hepatic safety profile 1, 2
• Ezetimibe is the preferred initial non-statin agent due to its demonstrated safety, tolerability, convenience, and single-tablet daily dose, particularly in patients with statin intolerance and elevated liver enzymes 1, 2

Efficacy and Safety of Ezetimibe

• As monotherapy, ezetimibe reduces LDL-C by approximately 18% 2
• The American College of Cardiology specifically recommends ezetimibe for diabetic patients who cannot tolerate statins 1, 3
• Ezetimibe has a favorable hepatic safety profile, making it suitable for patients with elevated ALT 1, 2

Treatment Guidelines

• Target LDL-C <100 mg/dL or at least 30-49% reduction from baseline for most diabetic patients 1, 3
• For higher-risk diabetic patients, target LDL-C <70 mg/dL 3, 5
• The recommended dose of ezetimibe is 10 mg orally once daily, with or without food 2
• Assess LDL-C response 4-12 weeks after initiation of ezetimibe therapy 1

Referral to a Lipid Specialist

• Refer patients with baseline LDL-C ≥190 mg/dL not due to secondary causes, complex mixed dyslipidemia, or severe hypertriglyceridemia to a lipid specialist 3, 4
• Consider referral if adequate LDL-C reduction is not achieved with ezetimibe plus bempedoic acid 4